Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Searle To Discuss Adding Celebrex 13-Month Safety Data To Label With FDA

Executive Summary

Searle plans to approach FDA with data from a 13-month trial comparing the ulcer incidence for Celebrex to other nonsteroidal anti-inflammatory drugs, seeking a label change for the COX-2 inhibitor.

You may also be interested in...



Pharmacia To Publish Full 12-Month Data From CLASS Study Of Celebrex

Pharmacia is preparing to publish the full 12-month data from the Celebrex CLASS GI outcomes study.

Pharmacia To Publish Full 12-Month Data From CLASS Study Of Celebrex

Pharmacia is preparing to publish the full 12-month data from the Celebrex CLASS GI outcomes study.

Celebrex, Vioxx GI Safety Data To Be Reviewed By FDA Committee Feb. 7-8

Applications to modify the NSAID class gastrointestinal safety labeling for the COX-2 inhibitors Celebrex and Vioxx will be reviewed by FDA's Arthritis Advisory Committee Feb. 7-8.

Related Content

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel